{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:20:03Z","timestamp":1785752403440,"version":"3.56.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fonds de la recherche du Qu\u00e9bec","award":["FRQ-S, #253895"],"award-info":[{"award-number":["FRQ-S, #253895"]}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT 168927, PJT 183735"],"award-info":[{"award-number":["PJT 168927, PJT 183735"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Research on the blood-brain barrier (BBB) has greatly evolved over the past 20 years, with growing recognition of its role as a multicellular complex regulating brain homeostasis. Previously confined to pharmaceutical sciences, the BBB has now become a growing focus of interest for neuroscientists and clinicians. However, the word \u2018barrier\u2019, implying something that can be broken, opened, or disrupted, can lead to confusion when one tries to relate this concept to its underlying cell biology. Here, echoing the fundamental question posed by Lina Stern when she first defined the BBB in 1921, I suggest that the confusion stems from conflating the physicochemical properties intrinsic to the barrier with the living biological multicellular interface. Notwithstanding its complexity, the BBB is now often simplistically portrayed as \u201cpermeable\u201d, particularly in the context of prevalent diseases, such as Alzheimer\u2019s, depression, multiple sclerosis, or stroke. Such overly simplified concepts promoted over the past two decades have led to misconceptions that hinder a proper understanding of the BBB, affecting both the general public and seasoned scientists. This misunderstanding is not without harmful clinical impact as many interpret the BBB as something that often breaks, leading to a massive entry of drugs and other blood-borne compounds into the brain, which is very rarely the case. After outlining the likely causes of these misconceptions and trying to define the concepts of \u201cBBB permeability\u201d and \u201cbrain bioavailability\u201d, I offer several recommendations: (1) more frequent use of quantitative methods involving small hydrophilic compounds to measure BBB integrity; (2) avoid terms such as \u2018BBB disruption,\u2019 \u2018opening,\u2019 or \u2018breakdown,\u2019 and instead favor terms like \u2018dysfunction\u2019 or, where appropriate, \u2018leakage\u2019, essentially when describing biological defects assessed by changes in large molecule localization; and (3) always account for the dual nature of the BBB, as both a physicochemical barrier and a living biological interface.<\/jats:p>","DOI":"10.1186\/s12987-025-00732-y","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:24:30Z","timestamp":1764249870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The duality of the BBB: breaking the myth of the blood-brain barrier breakdown"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4203-0887","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Calon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"732_CR1","unstructured":"Stern L. Le liquide c\u00e9phalo-rachidien au point de vue de ses rapports avec la circulation sanguine et avec les \u00e9l\u00e9ments nerveux de l\u2019axe c\u00e9r\u00e9brospinal. Schweiz Arch Neurol Psychiatr. 1921;8215\u2013232."},{"issue":"2","key":"732_CR2","first-page":"138","volume":"17","author":"L Stern","year":"1922","unstructured":"Stern L, Gautier R. Recherches sur le liquide c\u00e9phalo-rachidien: Les rapports entre le liquide c\u00e9phalo-rachidien et la circulation sanguine. Arch Int Physiol. 1922;17(2):138\u201392.","journal-title":"Arch Int Physiol"},{"key":"732_CR3","doi-asserted-by":"crossref","unstructured":"Stern L, Gautier R. Recherches Sur Le Liquide c\u00e9phalo-rachidien. Les rapports entre le liquide c\u00e9phalo-rachidien et les \u00e9l\u00e9ments nerveux de l\u2019axe c\u00e9r\u00e9bro-spinal. Arch Int Physiol. 1922;17(4):391\u2013448.","DOI":"10.3109\/13813452209146219"},{"key":"732_CR4","doi-asserted-by":"crossref","unstructured":"Banks WA, Rhea EM, Reed MJ, Erickson MA. The penetration of therapeutics across the blood-brain barrier: classic case studies and clinical implications. Cell Rep Med. 2024;5(11):101760.","DOI":"10.1016\/j.xcrm.2024.101760"},{"key":"732_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/pharmaceutics14061283","volume":"14","author":"WM Pardridge","year":"2022","unstructured":"Pardridge WM. A historical review of brain drug delivery. Pharmaceutics. 2022;14:6.","journal-title":"Pharmaceutics"},{"issue":"1","key":"732_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12987-023-00478-5","volume":"21","author":"J Badaut","year":"2024","unstructured":"Badaut J, Ghersi-Egea J-F, Thorne RG, Konsman JP. Blood-brain borders: a proposal to address limitations of historical blood-brain barrier terminology. Fluids Barriers CNS. 2024;21(1):3.","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"732_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8(1):217.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"732_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1152\/physrev.00050.2017","volume":"99","author":"MD Sweeney","year":"2019","unstructured":"Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-Brain barrier: from physiology to disease and back. Physiol Rev. 2019;99(1):21\u201378.","journal-title":"Physiol Rev"},{"issue":"1","key":"732_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.neuron.2017.07.030","volume":"96","author":"C Iadecola","year":"2017","unstructured":"Iadecola C. The neurovascular unit coming of age: A journey through neurovascular coupling in health and disease. Neuron. 2017;96(1):17\u201342.","journal-title":"Neuron"},{"issue":"1","key":"732_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1083\/jcb.34.1.207","volume":"34","author":"TS Reese","year":"1967","unstructured":"Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol. 1967;34(1):207\u201317.","journal-title":"J Cell Biol"},{"issue":"3","key":"732_CR11","first-page":"H299","volume":"235","author":"K Ohno","year":"1978","unstructured":"Ohno K, Pettigrew KD, Rapoport SI. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol. 1978;235(3):H299\u2013307.","journal-title":"Am J Physiol"},{"key":"732_CR12","doi-asserted-by":"crossref","unstructured":"Saunders NR, Dreifuss JJ, Dziegielewska KM, Johansson PA, Habgood MD, M\u00f8llg\u00e5rd K, Bauer HC. The rights and wrongs of blood-brain barrier permeability studies: a walk through 100 years of history. Front Neurosci. 2014;8404.","DOI":"10.3389\/fnins.2014.00404"},{"key":"732_CR13","doi-asserted-by":"crossref","unstructured":"Liddelow SA. Fluids and barriers of the CNS: a historical viewpoint. Fluids Barriers CNS. 2011;8.","DOI":"10.1186\/2045-8118-8-2"},{"key":"732_CR14","unstructured":"Goldmann EE. [C] Vitalf\u00e4rbung am zentralnervensystem: Beitrag zur Physio-Pathologie des plexus chorioideus und der Hirnh\u00e4ute. K\u00f6nigl. Akademie der Wissenschaften. 1913."},{"issue":"1","key":"732_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.it.2006.11.007","volume":"28","author":"I Bechmann","year":"2007","unstructured":"Bechmann I, Galea I, Perry VH. What is the blood-brain barrier (not)? Trends Immunol. 2007;28(1):5\u201311.","journal-title":"Trends Immunol"},{"issue":"1","key":"732_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1471-4159.2009.06544.x","volume":"113","author":"J Lichota","year":"2010","unstructured":"Lichota J, Skjorringe T, Thomsen LB, Moos T. Macromolecular drug transport into the brain using targeted therapy. J Neurochem. 2010;113(1):1\u201313.","journal-title":"J Neurochem"},{"issue":"51","key":"732_CR17","doi-asserted-by":"publisher","first-page":"32691","DOI":"10.1073\/pnas.1908658117","volume":"117","author":"S Dubey","year":"2020","unstructured":"Dubey S, Heinen S, Krantic S, McLaurin J, Branch DR, Hynynen K, Aubert I. Clinically approved IVIg delivered to the hippocampus with focused ultrasound promotes neurogenesis in a model of alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2020;117(51):32691\u2013700.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"732_CR18","doi-asserted-by":"crossref","unstructured":"Goutal S, et al. Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib. J Control Release. 2018;292210\u2013220.","DOI":"10.1016\/j.jconrel.2018.11.009"},{"key":"732_CR19","doi-asserted-by":"crossref","unstructured":"Goutal S, et al. Imaging the impact of blood-brain barrier disruption induced by focused ultrasound on P-glycoprotein function. J Control Release. 2023;361483\u2013492.","DOI":"10.1016\/j.jconrel.2023.08.012"},{"issue":"5","key":"732_CR20","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1021\/mp300495e","volume":"10","author":"DJ Wolak","year":"2013","unstructured":"Wolak DJ, Thorne RG. Diffusion of macromolecules in the brain: implications for drug delivery. Mol Pharm. 2013;10(5):1492\u2013504.","journal-title":"Mol Pharm"},{"issue":"3","key":"732_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1113\/JP275105","volume":"596","author":"ME Pizzo","year":"2018","unstructured":"Pizzo ME, et al. Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery. J Physiol. 2018;596(3):445\u201375.","journal-title":"J Physiol"},{"key":"732_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/ph14060535","volume":"14","author":"WM Pardridge","year":"2021","unstructured":"Pardridge WM, Chou T. Mathematical models of blood-brain barrier transport of monoclonal antibodies targeting the transferrin receptor and the insulin receptor. Pharmaceuticals (Basel). 2021;14:6.","journal-title":"Pharmaceuticals (Basel)"},{"key":"732_CR23","doi-asserted-by":"crossref","unstructured":"Mehta NH, et al. Quantifying cerebrospinal fluid dynamics: a review of human neuroimaging contributions to CSF physiology and neurodegenerative disease. Neurobiol Dis. 2022;170105776.","DOI":"10.1016\/j.nbd.2022.105776"},{"issue":"4","key":"732_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1177\/0271678X15608201","volume":"36","author":"S Paris-Robidas","year":"2016","unstructured":"Paris-Robidas S, Brouard D, Emond V, Parent M, Calon F. Internalization of targeted quantum dots by brain capillary endothelial cells in vivo. J Cereb Blood Flow Metab. 2016;36(4):731\u201342.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"11","key":"732_CR25","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s11095-013-1119-z","volume":"30","author":"C Passeleu-Le Bourdonnec","year":"2013","unstructured":"Passeleu-Le Bourdonnec C, Carrupt PA, Scherrmann JM, Martel S. Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research. Pharm Res. 2013;30(11):2729\u201356.","journal-title":"Pharm Res"},{"issue":"2","key":"732_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/00004647-200002000-00020","volume":"20","author":"C Dagenais","year":"2000","unstructured":"Dagenais C, Rousselle C, Pollack GM, Scherrmann JM. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab. 2000;20(2):381\u20136.","journal-title":"J Cereb Blood Flow Metab"},{"key":"732_CR27","doi-asserted-by":"crossref","unstructured":"Abraham MH, Chadha HS, Mitchell RC, Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. J Pharm Sci. 1994;83(9):1257\u20131268.","DOI":"10.1002\/jps.2600830915"},{"issue":"2","key":"732_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1021\/mp5005965","volume":"12","author":"I Loryan","year":"2015","unstructured":"Loryan I, et al. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates. Mol Pharm. 2015;12(2):520\u201332.","journal-title":"Mol Pharm"},{"issue":"11","key":"732_CR29","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959\u201372.","journal-title":"J Cereb Blood Flow Metab"},{"key":"732_CR30","doi-asserted-by":"crossref","unstructured":"Yao L, Xue X, Yu P, Ni Y, Chen F. Evans blue dye: a revisit of its applications in biomedicine. Contrast Media Mol Imaging. 2018;20187628037.","DOI":"10.1155\/2018\/7628037"},{"issue":"2","key":"732_CR31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1083\/jcb.139.2.375","volume":"139","author":"V Straub","year":"1997","unstructured":"Straub V, Rafael JA, Chamberlain JS, Campbell KP. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol. 1997;139(2):375\u201385.","journal-title":"J Cell Biol"},{"issue":"1","key":"732_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0165-0270(83)90050-X","volume":"8","author":"A Saria","year":"1983","unstructured":"Saria A, Lundberg JM. Evans blue fluorescence: quantitative and morphological evaluation of vascular permeability in animal tissues. J Neurosci Methods. 1983;8(1):41\u20139.","journal-title":"J Neurosci Methods"},{"issue":"1","key":"732_CR33","doi-asserted-by":"publisher","first-page":"11081","DOI":"10.1038\/s41598-023-37280-0","volume":"13","author":"L Reveret","year":"2023","unstructured":"Reveret L, Leclerc M, Morin F, \u00c9mond V, Calon F. Pharmacokinetics, biodistribution and toxicology of novel cell-penetrating peptides. Sci Rep. 2023;13(1):11081.","journal-title":"Sci Rep"},{"issue":"12","key":"732_CR34","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/jcbfm.2013.160","volume":"33","author":"I St-Amour","year":"2013","unstructured":"St-Amour I, et al. Brain bioavailability of human intravenous Immunoglobulin and its transport through the murine blood-brain barrier. J Cereb Blood Flow Metab. 2013;33(12):1983\u201392.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"732_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1208\/s12248-023-00812-7","volume":"25","author":"S Liu","year":"2023","unstructured":"Liu S, Shah DK. Physiologically based Pharmacokinetic modeling to characterize the effect of molecular charge on whole-body disposition of monoclonal antibodies. AAPS J. 2023;25(3):48.","journal-title":"AAPS J"},{"key":"732_CR36","unstructured":"Bourasset F, Auvity S, Thorne RG, Scherrmann JM. Brain distribution of drugs: brain Morphology, delivery Routes, and species differences. Handb Exp Pharmacol. 2022;27397\u2013120."},{"issue":"1\u20132","key":"732_CR37","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s11010-011-0910-6","volume":"357","author":"TM Do","year":"2011","unstructured":"Do TM, Ouellet M, Calon F, Chimini G, Chacun H, Farinotti R, Bourasset F. Direct evidence of abca1-mediated efflux of cholesterol at the mouse blood-brain barrier. Mol Cell Biochem. 2011;357(1\u20132):397\u2013404.","journal-title":"Mol Cell Biochem"},{"issue":"5","key":"732_CR38","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1161\/01.ATV.0000120374.59826.1b","volume":"24","author":"I Bj\u00f6rkhem","year":"2004","unstructured":"Bj\u00f6rkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004;24(5):806\u201315.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"732_CR39","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1021\/bc0155061","volume":"12","author":"HJ Lee","year":"2001","unstructured":"Lee HJ, Pardridge WM. Pharmacokinetics and delivery of Tat and Tat-protein conjugates to tissues in vivo. Bioconjug Chem. 2001;12(6):995\u20139.","journal-title":"Bioconjug Chem"},{"issue":"6","key":"732_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.tips.2020.03.004","volume":"41","author":"M Davies","year":"2020","unstructured":"Davies M, et al. Improving the accuracy of predicted human pharmacokinetics: lessons learned from the AstraZeneca drug pipeline over two decades. Trends Pharmacol Sci. 2020;41(6):390\u2013408.","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"732_CR41","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1124\/dmd.118.081893","volume":"46","author":"DR Goulet","year":"2018","unstructured":"Goulet DR, Watson MJ, Tam SH, Zwolak A, Chiu ML, Atkins WM, Nath A. Toward a combinatorial approach for the prediction of IgG Half-Life and clearance. Drug Metab Dispos. 2018;46(12):1900\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"22","key":"732_CR42","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1111\/bph.14021","volume":"174","author":"DB Yadav","year":"2017","unstructured":"Yadav DB, et al. Widespread brain distribution and activity following i.c.v. Infusion of anti-\u03b2-secretase (BACE1) in nonhuman primates. Br J Pharmacol. 2017;174(22):4173\u201385.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"732_CR43","doi-asserted-by":"publisher","first-page":"108132","DOI":"10.1016\/j.isci.2023.108132","volume":"26","author":"L Schellhammer","year":"2023","unstructured":"Schellhammer L, Beffinger M, Salazar U, Laman JD, Buch T, Vom Berg J. Exit pathways of therapeutic antibodies from the brain and retention strategies. iScience. 2023;26(11):108132.","journal-title":"iScience"},{"key":"732_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/ijms22073356","volume":"22","author":"M Leclerc","year":"2021","unstructured":"Leclerc M, Dudonn\u00e9 S, Calon F. Can natural products exert neuroprotection without crossing the Blood-Brain barrier. Int J Mol Sci. 2021;22:7.","journal-title":"Int J Mol Sci"},{"key":"732_CR45","unstructured":"Reiber H. Disease-related data patterns in cerebrospinal fluid diagnostics: medical quality versus analytical quantity. Front Mol Biosci. 2024;111348091."},{"issue":"5","key":"732_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/00007256-200838050-00004","volume":"38","author":"H Zouhal","year":"2008","unstructured":"Zouhal H, Jacob C, Delamarche P, Gratas-Delamarche A. Catecholamines and the effects of exercise, training and gender. Sports Med. 2008;38(5):401\u201323.","journal-title":"Sports Med"},{"issue":"1","key":"732_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00421-003-1002-4","volume":"91","author":"C Jacob","year":"2004","unstructured":"Jacob C, Zouhal H, Prioux J, Gratas-Delamarche A, Bentu\u00e9-Ferrer D, Delamarche P. Effect of the intensity of training on catecholamine responses to supramaximal exercise in endurance-trained men. Eur J Appl Physiol. 2004;91(1):35\u201340.","journal-title":"Eur J Appl Physiol"},{"issue":"7","key":"732_CR48","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/brainsci11070829","volume":"11","author":"A Marques","year":"2021","unstructured":"Marques A, et al. Bidirectional association between physical activity and dopamine across Adulthood-A systematic review. Brain Sci. 2021;11(7):829.","journal-title":"Brain Sci"},{"key":"732_CR49","unstructured":"Hales CM, Servais J, Martin CB, Kohen D. Prescription drug use among adults aged 40\u201379 in the united States and Canada. NCHS Data Brief. 2019;347:1\u20138."},{"issue":"1","key":"732_CR50","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12987-025-00688-z","volume":"22","author":"S Lemarchant","year":"2025","unstructured":"Lemarchant S, et al. Restoring brain barriers: an innovative approach for treating neurological disorders. Fluids Barriers CNS. 2025;22(1):72.","journal-title":"Fluids Barriers CNS"},{"issue":"8","key":"732_CR51","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1177\/0271678X241237484","volume":"44","author":"M Leclerc","year":"2024","unstructured":"Leclerc M, Tremblay C, Bourassa P, Schneider JA, Bennett DA, Calon F. Lower GLUT1 and unchanged MCT1 in alzheimer\u2019s disease cerebrovasculature. J Cereb Blood Flow Metab. 2024;44(8):1417\u201332.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"732_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/brain\/awac309","volume":"146","author":"M Leclerc","year":"2023","unstructured":"Leclerc M, et al. Cerebrovascular insulin receptors are defective in alzheimer\u2019s disease. Brain. 2023;146(1):75\u201390.","journal-title":"Brain"},{"issue":"4","key":"732_CR53","doi-asserted-by":"publisher","first-page":"e20190062","DOI":"10.1084\/jem.20190062","volume":"217","author":"CP Profaci","year":"2020","unstructured":"Profaci CP, Munji RN, Pulido RS, Daneman R. The blood-brain barrier in health and disease: important unanswered questions. J Exp Med. 2020;217(4):e20190062.","journal-title":"J Exp Med"},{"issue":"4","key":"732_CR54","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/mrm.22686","volume":"65","author":"S Taheri","year":"2011","unstructured":"Taheri S, Gasparovic C, Shah NJ, Rosenberg GA. Quantitative measurement of blood-brain barrier permeability in human using dynamic contrast-enhanced MRI with fast T1 mapping. Magn Reson Med. 2011;65(4):1036\u201342.","journal-title":"Magn Reson Med"},{"issue":"3","key":"732_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133\u201350.","journal-title":"Nat Rev Neurol"},{"issue":"23","key":"732_CR56","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","volume":"16","author":"PR Lockman","year":"2010","unstructured":"Lockman PR, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16(23):5664\u201378.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"732_CR57","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/cancers17020298","volume":"17","author":"JJ Peters","year":"2025","unstructured":"Peters JJ, Teng C, Peng K, Li X. Deciphering the blood-brain barrier paradox in brain metastasis development and therapy. Cancers (Basel). 2025;17(2):298.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"732_CR58","first-page":"vdae201","volume":"7","author":"AM Giantini-Larsen","year":"2025","unstructured":"Giantini-Larsen AM, et al. Therapeutic manipulation and bypass of the blood-brain barrier: powerful tools in glioma treatment. Neurooncol Adv. 2025;7(1):vdae201.","journal-title":"Neurooncol Adv"},{"issue":"3","key":"732_CR59","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molmed.2023.12.006","volume":"30","author":"RH Kofoed","year":"2024","unstructured":"Kofoed RH, Aubert I. Focused ultrasound gene delivery for the treatment of neurological disorders. Trends Mol Med. 2024;30(3):263\u201377.","journal-title":"Trends Mol Med"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-025-00732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-025-00732-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-025-00732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:01:52Z","timestamp":1781618512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12987-025-00732-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["732"],"URL":"https:\/\/doi.org\/10.1186\/s12987-025-00732-y","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}